Literature DB >> 6182113

Human interferon inhibits the growth of established human breast tumours in the nude mouse.

F R Balkwill, E M Moodie, V Freedman, K H Fantes.   

Abstract

In this paper we describe a model system for looking at the effects of human interferon, IFN, on an established human tumour. Highly purified human IFN derived from lymphoblastoid cells (HuIFN alpha-Namalwa) strongly inhibited the growth of a human breast cancer growing as a xenograft in nude mice. The effect was dose-dependent, required daily treatment for an optimal effect and was time-dependent, little inhibition being seen before 2 weeks of therapy. With the doses used, however, neither tumour regression nor disappearance were seen and on morphological examination, treated tumours appeared as miniatures of control tumours. The inhibition of the tumour by HuIFN alpha-Namalwa appeared to be due to a direct effect on the human cells as this IFN had little effect on the mouse immune system in vitro as measured by NK cells activity. Also HuIFN therapy had no effect on levels of an interferon induced enzyme, 2-5A synthetase, in the mouse spleen cells but stimulated this enzyme in the human tumour.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182113     DOI: 10.1002/ijc.2910300217

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 2.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 3.  Interferon in 1987: the half full glass.

Authors:  S E Krown
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

4.  Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.

Authors:  S A Kadhim; J L Chin
Journal:  Urol Res       Date:  1991

5.  Novel therapy for the treatment of human carcinoid.

Authors:  B M Evers; S C Hurlbut; S K Tyring; C M Townsend; T Uchida; J C Thompson
Journal:  Ann Surg       Date:  1991-05       Impact factor: 12.969

6.  Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.

Authors:  G Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; D D Von Hoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

7.  The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts.

Authors:  L Ozzello; C M De Rosa; E W Blank; K Cantell; R L Ceriani; D V Habif
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  In vitro antiproliferative efficacy of interferon-alpha, -gamma and tumor necrosis factor on two human renal tumor xenografts.

Authors:  A J Beniers; W P Peelen; B T Hendriks; J A Schalken; J C Romijn; F M Debruyne
Journal:  Urol Res       Date:  1988

Review 9.  The antitumor effects of interferon.

Authors:  I Gresser
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

10.  Increased epidermal growth factor receptor gene expression by gamma-interferon in a human breast carcinoma cell line.

Authors:  A W Hamburger; G D Pinnamaneni
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.